Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of this agreement, Novartis Pharma and Otsuka will jointly undertake the promotion of LCZ696 to healthcare practitioners in Japan.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: LCZ696
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: $90.0 million
Deal Type: Agreement March 02, 2020